Skip to main content
Premium Trial:

Request an Annual Quote

Akoya Receives CLIA Certification for Biopharma Solutions Laboratory

NEW YORK – Akoya Biosciences said Tuesday that it has received CLIA certification for its Advanced Biopharma Solutions laboratory.

The Marlborough, Massachusetts-based firm said that the certification would allow it to support later-stage clinical trials with its biopharma partners and was a step toward advancing its spatial imaging platform for clinical use.

"Securing CLIA certification for ABS demonstrates our commitment to meeting the highest quality standards,” Akoya CEO Brian McKelligon said in a statement. "This is an important step in support of our effort to work with our biopharmaceutical partners to identify biomarkers that lead to better clinical decision making and improved patient outcomes."

On the company's Q3 2021 earnings call, McKelligon said Akoya has inked a number of agreements with biopharma firms for fee-for-service work on clinical trial samples using its Phenoptics single-cell imaging system, which is aimed at the translational and clinical markets.

It also has ongoing collaborations with pharma companies, including AstraZeneca, with which it signed a partnership in June for spatial biomarker analysis for immuno-oncology drug development.

The Scan

Sensor to Spot SARS-CoV-2 Exposure

Yale researchers have developed a sensor that gauges SARS-CoV-2 exposure, according to the New Haven Register.

Watching BA.2

A subtype of the Omicron SARS-CoV-2 variant has been found in a number of countries, the Washington Post says.

Vermont Weighs Genetic Discrimination Bill

VT Digger reports Vermont legislators are considering a bill to bar insurer from denying customers coverage based on genetic information.

PNAS Papers on Convergent Pathogen Effectors, Lineage-Related RNA Mutations, Desiccation-Tolerant Grass

In PNAS this week: convergent evolution of pathogen effectors, algorithm to identify cell lineage features, and more.